e-Article
A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation
Document Type
Article
Author
Source
In American Journal of Transplantation January 2020 20(1):172-180
Subject
Language
ISSN
1600-6135